We’re heading to the #ASFA2026 Annual Meeting‼️ NMDP is proud to join the global apheresis community to share new research and connect with peers from around the world.

📊 We’ll be sharing research focused on optimizing donor mobilization and improving collection outcomes. We hope to see you there!

⏰ 6 days left to register for: 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐃𝐨𝐧𝐨𝐫 𝐒𝐞𝐚𝐫𝐜𝐡 & 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧: 𝐔𝐩𝐝𝐚𝐭𝐞𝐝 𝐆𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞𝐬 & 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬.

Using real-world cases, experts will show how to apply updated donor selection guidance + evaluate alternative options when a fully matched donor isn’t available.
🔗: lnkd.in/eDyJPV3E

🎬 That’s a wrap on EBMT in Madrid!

From sharing new research, to connecting with colleagues across the globe, NMDP and @cibmtr.bsky.social were proud to be part of the European Society for Blood and Marrow Transplantation 52nd Annual Meeting.

What was your favorite #EBMT26 moment? ⬇️

🚨 New data from the ACCESS trial continues to strengthen the case for MMUD transplantation in the PTCy era.

Join Monzr Al Malki at EBMT to see how longer-term survival & GVHD outcomes support MMUD as a viable, effective donor option—and what these findings mean for expanding access to transplant.

📊 EBMT is here—and so is your chance to meet the expert physicians behind the groundbreaking NMDP/CIBMTR data‼️

📍 Stop by Booth 41 to chat with Dr. Steven Devine and Dr. Jeffrey Auletta. Bring your questions. Review the data. Continue the discussion.

🔬 At EBMT, NMDP and CIBMTR will share new data that could help inform clinical decision-making in modern transplant practice.

If you're attending #EBMT, add these to your agenda! ⬇️

Attending #EBMT? Join CIBMTR oral sessions with Steven Devine and Jeffrey Auletta exploring the latest evidence on donor selection, immune recovery and GVHD prevention in modern transplant practice.

On March 23, they’ll present new data on how transplant strategy is evolving in the post-PTCy era ⬇️

🚨 Join us for an interactive webinar designed to strengthen understanding and confidence in allogeneic donor selection for hematopoietic cell transplantation: "𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐃𝐨𝐧𝐨𝐫 𝐒𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧: 𝐔𝐩𝐝𝐚𝐭𝐞𝐝 𝐆𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞𝐬 & 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬."

Register now: go.nmdp.org/4lh14Oj

Is it time to redefine the "gold standard" for AML chemotherapy?

For decades, intensive induction chemotherapy (IC) has been the default for fit adults with newly diagnosed AML. However, the Phase II PARADIGM study results suggest a new path forward. 👉Full abstract from #ASH25: go.nmdp.org/3MxtIO2

A University of Arkansas student’s life-saving blood stem cell donation | NMDP Kara joined the NMDP Registry at a sorority event and became a blood stem cell donor. Discover how you could help save a life, too.

This is Kara.

She joined the NMDP Registry at a campus drive and became a blood stem cell donor just months later. With a family connection to the very beginnings of our registry, saying yes had a special meaning. 💙

She gave someone a second chance and you can too 👉 go.nmdp.org/gokara

It's the final day to come see us at #Tandem26!
📍 Visit NMDP at Booth #T430 to connect with our team
➕ Complete the Lifesaver Loop by visiting our partners and learning of our impactful collaboration for a chance to win a prize!

🏆 NMDP is proud to receive the ASTCT Public Service Award at #Tandem2026, with CEO Amy Ronneberg recognized on behalf of our org.

Since 1987, NMDP has advanced transplantation & access to cell therapy—impacting 140,000+ lives. We thank ASTCT for recognizing that commitment with a meaningful honor!

⏰ One hour could change how your team saves lives.

Join NMDP at #Tandem26 for a Pathways to Transplant Networking Lunch to discuss:
✔️Timely referral, consultation & continuity of care
✔️Barriers, referral challenges & ways to optimize care team coordination

Feb 6|12–1:30PM
RSVP: go.nmdp.org/4r6EUQx

HLA Mismatch Levels Show Comparable Survival, PROs | NMDP NMDP-sponsored ACCESS trial data presented at the 2026 Tandem Meetings show comparable patient-reported outcomes and survival, even for <7/8 matches. Read the results.

🔬 NMDP and CIBMTR are presenting new findings from the ACCESS study at #Tandem2026.

These new findings highlight important dimensions of transplant outcomes and patient experience following mismatched unrelated donor (MMUD) transplantation 👉 go.nmdp.org/Tandem2026

It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️

At #Tandem26, NMDP and ASTCT are hosting a Spotlight Session on the ACCESS Initiative—a collaborative effort to reduce barriers to transplant and cell therapy and improve outcomes for all patients.

🔗 Add this to your Tandem schedule: go.nmdp.org/4r5ub91
🗓️ Feb. 5 | 3–5 p.m
🎓 CME credits available

The NMDP/CIBMTR community is excited to present featured research at #Tandem2026 next week.

Add these to your calendar to engage with research driving innovation, expanding donor options and improving outcomes for patients.

Last chance to register for Session 3 of Project ECHO: Coordinated Care from Treatment to Survivorship.

🗓️ Jan. 28 | 5–6 PM ET
Learn best practices for post-treatment monitoring, relapse surveillance after allogeneic HCT and CAR T-cell therapy + care coordination across teams.
🔗 go.nmdp.org/3JJdVdS

Thanks for joining in to help the thousands of patients like Ed who are searching for their life-saving donor. 💙

Thanks for joining in to help the thousands of patients like Ed who are searching for their life-saving donor. 💙

Thanks for joining in to help the thousands of patients like Ed searching for their life-saving donor. 💙

⚠️ Kiri urgently needs a blood stem cell donor.

He has a rare genetic disorder called ALD that is progressing, and you could be the matching donor he needs so he can grow up to be a firefighter just like his dad.

Find out how to can help go.nmdp.org/supportkiri

Attending the #Tandem26 Meetings? Save the date for the NMDP Reception!

📅February 5 |7–10 PM
📍Hyatt Regency

Enjoy...
✔️ Networking
✔️ Honoring this year’s NMDP Amy Strelzer Manasevit Research Program and Barbara Buchbinder Nurse Research Program grant recipients
✔️ A powerful donor–recipient meeting

 🎂 Imagine getting a call on your birthday saying you could help save a life. That’s what happened to Mitch!
 
He donated blood stem cells in 2020 and AGAIN five years later to the same patient, giving them renewed hope. Find out how you can give someone a second chance too: go.nmdp.org/gomitch

Potential Game-Changing Impact on Mismatched Unrelated Blood Cell Transplantation Similar survival, GVHD rates with 7/8 or <7/8 HLA matching, with post-transplant cylophosphamide

Fresh off ASH, our research is now featured in MedPage Today‼️

The new ACCESS trial results show that patients who receive suitably matched donor grafts at &lt;7/8 HLA can achieve one-year survival outcomes comparable to those of more closely matched donors when PTCy is used.
🔗 bit.ly/MedPageACCESS

⚠️ Let’s help Vivian get the second chance she deserves!

She’s fighting leukemia with courage, but she still needs a matching blood stem cell donor who can give her more time with her family.

Share or join the registry to help her find her match: 👉 go.nmdp.org/supportvivian

We were honored to be joined by Robin Roberts at this year’s #ONEForum2025. Robin joined our CEO Amy Ronneberg for a fireside chat and was later presented with the Inspire Award for the incredible work she’s done advocating for NMDP’s lifesaving mission. THANK YOU, Robin! 

💭 As #ASH25 comes to a close, we’re reflecting on the research shared, collaborations sparked and innovations underway—with gratitude and hope that one day every patient with a blood cancer or disorder can access life-saving care. 

⬇️ What was your favorite moment from ASH?

🔎 Make sure your Monday at #ASH25 includes ➡️ Advancing Donor for All. This NMDP initiative is driving new research, data science and operational innovation to expand donor options and improve outcomes for every patient — regardless of ancestry.

🔬 What if diagnosing and tracking AML could be done with one test? 

At #ASH25, NMDP is sharing new MEASURE study results showing whole genome sequencing (WGS) can identify key AML mutations and offer clearer, more consistent data—moving us closer to modernized diagnosis and monitoring.  ⬇️